Novo Nordisk ( NVO ) recently
announced the successful completion of a single dose phase I study
on OI362GT (NN1954).
OI362GT is a long-acting oral basal insulin analogue being
developed as a tablet treatment for type I and type II
The double-blind, randomized, placebo and active controlled
study evaluated the safety, tolerability, pharmacokinetics
(exposure of drug) and pharmacodynamics (effect on blood glucose
levels) of the candidate.
Merrion and Novo Nordisk's association goes back to Nov 2008
when the companies entered into an agreement to develop and
commercialize oral formulations of Novo Nordisk's OI362GT, using
Merrion's GIPET technology (Gastrointestinal Permeation Enhancement
Technology). As per the agreement, Merrion is entitled to receive
development, regulatory and sales-based milestone payments as well
as royalties on sales.
We are pleased with Novo Nordisk's efforts to strengthen its
presence in the diabetes market. Currently, Novo Nordisk is looking
towards its two newly approved diabetes drugs, Tresiba and Ryzodeg,
for driving long-term growth.
In Jan 2013, Novo Nordisk received approval in the EU (covering
all 27 states) for both Tresiba and Ryzodeg. In the EU, Novo
Nordisk is planning to launch Tresiba first and Ryzodeg a year
later. Tresiba and Ryzodeg will be available in Novo Nordisk's
latest prefilled insulin pen named FlexTouch in Europe. The
Japanese Ministry of Health, Labour and Welfare (MHLW) approved
Tresiba and Ryzodeg for the treatment of diabetes in September and
Dec 2012, respectively.
Novo Nordisk currently carries a Zacks Rank #2 (Buy). Currently,
companies like Lannett Company, Inc. ( LCI ),
UCB ( UCBJF ) and
WuXi Pharma Tech (Cayman) Inc. ( WX ) look more
attractive with a Zacks Rank #1 (Strong Buy).LANNETT INC (LCI): Free Stock Analysis ReportNOVO-NORDISK AS (NVO): Free Stock Analysis
ReportUCB SA (UCBJF): Get Free ReportWUXI PHARMATECH (WX): Free Stock Analysis
ReportTo read this article on Zacks.com click here.Zacks Investment